🇺🇸 FDA
Patent

US 12221441

Plasma kallikrein inhibitors and uses thereof

granted A61PA61P29/00A61P9/00

Quick answer

US patent 12221441 (Plasma kallikrein inhibitors and uses thereof) held by Takeda Pharmaceutical Company Limited expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P29/00, A61P9/00